Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 19/20 | 0.67 |
| ▸ | CDK1 | P06493 | 12/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 12/20 | 0.67 |
| ▸ | CCND1 | P24385 | 11/20 | 0.67 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.67 |
| ▸ | CDK4 | P11802 | 9/20 | 0.67 |
| ▸ | CCND3 | P30281 | 9/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.67 |
| ▸ | CDK7 | P50613 | 4/20 | 0.67 |
| ▸ | CDK9 | P50750 | 4/20 | 0.67 |
| ▸ | CCNH | P51946 | 4/20 | 0.67 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26941950 | 0.87 | CDK2 (0.65) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL27359317 | 0.87 | CDK2 (0.84) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL30449148 | 0.83 | CCNE1 (0.67) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL22900798 | 0.83 | CCNE1 (0.67) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL22977348 | 0.83 | CDK2 (0.71) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL26942015 | 0.83 | CDK2 (0.62) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL22901105 | 0.83 | CCNE1 (0.65) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL29631651 | 0.83 | CCNE1 (0.65) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL26918950 | 0.83 | CCR6 (0.48) | CDK2CCNE1CDK1CCNB1CCND1 | |
| SCHEMBL24477981 | 0.82 | CDK2 (0.53) | CDK2CCNE1CDK1CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250009745-A1 | CDK INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2025-01-09 | — | — | US | disclosed |
| US-20240352029-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-10-24 | — | — | US | disclosed |
| WO-2024216249-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240246993-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-07-25 | — | — | US | disclosed |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11939340-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-26 | — | — | US | disclosed |
| CN-116348458-A | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors | 因赛特公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022166793-A1 | CDK INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2022-08-11 | — | — | WO | disclosed |
| EP-4013750-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009745-A1 | CDK INHIBITOR | CDK9, CDKL1, CDK6 | CDK2 11/4885CCNE1 32/4885CDK1 8/4885 |
| US-11939340-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CDK2 4/4885CCNE1 36/4885CDK1 2/4885 |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CDK2 1/4885CCNE1 43/4885CDK1 7/4885 |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CDK2 1/4885CCNE1 43/4885CDK1 7/4885 |
| US-20240246993-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDK2 4/4885CCNE1 36/4885CDK1 2/4885 |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CDK2 1/4885CCNE1 43/4885CDK1 7/4885 |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDK2 4/4885CCNE1 36/4885CDK1 2/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CDK2 1/4885CCNE1 43/4885CDK1 7/4885 |
| US-20240352029-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDK2 4/4885CCNE1 36/4885CDK1 2/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CDK2 1/4885CCNE1 43/4885CDK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.